NCT07356050Recruiting
Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease
Children's Hospital Medical Center, Cincinnati
Start Date
3/13/2025
Completion Date
12/31/2028
Summary
The goal of this study is to learn if infants with sickle cell disease (SCD) develop adequate protection after measles vaccines. (not looking at any prolonged duration)
Detailed Description
Families of infants with SCD who are eligible for a measles vaccine per standard care will be contacted to discuss enrollment in the study. One cohort will be evaluated for response to the first measles vaccine (MV1) and another cohort will be evaluated for response to the second measles vaccine (MV2). Blood samples will be collected from participants prior to measles vaccination and then again at 4 and 8 weeks after vaccination.
Eligibility Criteria
Age Range: No minimum to 6 years
Inclusion Criteria:
1. Participants with confirmed Sickle Cell Disease.
2. Participants 6 months and 6 years of age and due for measles vaccination within 3 months per national guidelines.
3. Willing and able to provide informed consent
4. Ability to comply with study related evaluations and follow-up visits.
Exclusion Criteria:
1\. Known primary immunodeficiency syndrome, cancer, or acquired immunodeficiency syndrome (AIDS) that would preclude vaccination with live virus vaccines.
Conditions
Sickle Cell DiseaseMeasles VaccinationSickle Cell Anemia
Locations
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio 45229
United States
Korle Bu Teaching Hospital
Accra, Ghana
Ghana
Bugando Medical Centre
Mwanza,
Tanzania